COSCIENS Biopharma Past Earnings Performance
Past criteria checks 0/6
COSCIENS Biopharma's earnings have been declining at an average annual rate of -31.9%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been growing at an average rate of 20.1% per year.
Key information
-31.9%
Earnings growth rate
19.5%
EPS growth rate
| Biotechs Industry Growth | 51.1% |
| Revenue growth rate | 20.1% |
| Return on equity | -116.0% |
| Net Margin | -480.1% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
We're Hopeful That Aeterna Zentaris (TSE:AEZS) Will Use Its Cash Wisely
May 10
We're Interested To See How Aeterna Zentaris (TSE:AEZS) Uses Its Cash Hoard To Grow
Nov 12Here's Why We're Not At All Concerned With Aeterna Zentaris' (TSE:AEZS) Cash Burn Situation
Jul 15Companies Like Aeterna Zentaris (TSE:AEZS) Can Afford To Invest In Growth
Mar 29Reflecting on Aeterna Zentaris' (TSE:AEZS) Share Price Returns Over The Last Five Years
Feb 04Revenue & Expenses Breakdown
How COSCIENS Biopharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 5 | -23 | 13 | 17 |
| 30 Jun 24 | 5 | -18 | 7 | 15 |
| 31 Mar 24 | 4 | -18 | 5 | 14 |
| 31 Dec 23 | 4 | -17 | 9 | 14 |
| 30 Sep 23 | 6 | -18 | 6 | 8 |
| 30 Jun 23 | 8 | -17 | 7 | 9 |
| 31 Mar 23 | 7 | -20 | 8 | 11 |
| 31 Dec 22 | 6 | -23 | 8 | 13 |
| 30 Sep 22 | 4 | -13 | 8 | 10 |
| 30 Jun 22 | 3 | -12 | 8 | 8 |
| 31 Mar 22 | 5 | -10 | 8 | 8 |
| 31 Dec 21 | 5 | -8 | 7 | 7 |
| 30 Sep 21 | 7 | -7 | 7 | 5 |
| 30 Jun 21 | 6 | -6 | 7 | 4 |
| 31 Mar 21 | 4 | -7 | 6 | 3 |
| 31 Dec 20 | 4 | -5 | 6 | 2 |
| 30 Sep 20 | 1 | -5 | 6 | 1 |
| 30 Jun 20 | 1 | -4 | 6 | 1 |
| 31 Mar 20 | 2 | 0 | 7 | 2 |
| 31 Dec 19 | 1 | -6 | 8 | 2 |
| 30 Sep 19 | 2 | -10 | 8 | 2 |
| 30 Jun 19 | 2 | -12 | 9 | 2 |
| 31 Mar 19 | 2 | -15 | 10 | 3 |
| 31 Dec 18 | 27 | 4 | 12 | 3 |
| 30 Sep 18 | 26 | 9 | 13 | 0 |
| 30 Jun 18 | 25 | 2 | 13 | 4 |
| 31 Mar 18 | 25 | 2 | 14 | 7 |
| 31 Dec 17 | 1 | -17 | 13 | 11 |
| 30 Sep 17 | 1 | -25 | 13 | 15 |
| 30 Jun 17 | 1 | -21 | 13 | 15 |
| 31 Mar 17 | 1 | -25 | 14 | 15 |
| 31 Dec 16 | 1 | -25 | 14 | 16 |
| 30 Sep 16 | 1 | -27 | 16 | 16 |
| 30 Jun 16 | 1 | -36 | 16 | 16 |
| 31 Mar 16 | 1 | -44 | 17 | 16 |
| 31 Dec 15 | 1 | -50 | 18 | 17 |
| 30 Sep 15 | 0 | -36 | 17 | 18 |
| 30 Jun 15 | 0 | -32 | 17 | 19 |
| 31 Mar 15 | 0 | -23 | 16 | 20 |
| 31 Dec 14 | 0 | -17 | 14 | 22 |
| 30 Sep 14 | 0 | -32 | 10 | 21 |
| 30 Jun 14 | 0 | -28 | 10 | 23 |
| 31 Mar 14 | 0 | -33 | 10 | 23 |
| 31 Dec 13 | 6 | -27 | 10 | 21 |
Quality Earnings: CSCI is currently unprofitable.
Growing Profit Margin: CSCI is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CSCI is unprofitable, and losses have increased over the past 5 years at a rate of 31.9% per year.
Accelerating Growth: Unable to compare CSCI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CSCI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: CSCI has a negative Return on Equity (-115.96%), as it is currently unprofitable.